[go: up one dir, main page]

MX2018011046A - Composiciones y metodos para tratar canceres. - Google Patents

Composiciones y metodos para tratar canceres.

Info

Publication number
MX2018011046A
MX2018011046A MX2018011046A MX2018011046A MX2018011046A MX 2018011046 A MX2018011046 A MX 2018011046A MX 2018011046 A MX2018011046 A MX 2018011046A MX 2018011046 A MX2018011046 A MX 2018011046A MX 2018011046 A MX2018011046 A MX 2018011046A
Authority
MX
Mexico
Prior art keywords
methods
compositions
treating cancers
galectin
aml
Prior art date
Application number
MX2018011046A
Other languages
English (en)
Inventor
Chiriva-Internati Maurizio
Mirandola Leonardo
Original Assignee
Kiromic Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kiromic Inc filed Critical Kiromic Inc
Publication of MX2018011046A publication Critical patent/MX2018011046A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4726—Lectins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1732—Lectins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

Composiciones y métodos para tratar cánceres sólidos y hematológicos, que incluyen leucemia mieloide aguda (AML), se proporcionan en este documento. Los métodos incluyen administrar formas negativas dominantes, truncadas de galectina-3.
MX2018011046A 2016-03-14 2017-03-13 Composiciones y metodos para tratar canceres. MX2018011046A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662308045P 2016-03-14 2016-03-14
PCT/US2017/022168 WO2017160761A2 (en) 2016-03-14 2017-03-13 Compositions and methods for treating cancers

Publications (1)

Publication Number Publication Date
MX2018011046A true MX2018011046A (es) 2019-05-06

Family

ID=59851561

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018011046A MX2018011046A (es) 2016-03-14 2017-03-13 Composiciones y metodos para tratar canceres.

Country Status (5)

Country Link
US (1) US10717774B2 (es)
EP (1) EP3429613A4 (es)
CN (1) CN109310738A (es)
MX (1) MX2018011046A (es)
WO (1) WO2017160761A2 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109310738A (zh) 2016-03-14 2019-02-05 克罗米科股份有限公司 用于治疗癌症的组合物和方法
TWI794171B (zh) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
EP3883560A1 (en) * 2018-11-19 2021-09-29 Unichem Laboratories Limited Combination of chemotherapy with recombinant s. rolfsii lectin
US20230000896A1 (en) * 2019-12-09 2023-01-05 President And Fellows Of Harvard College Aldh3a2 inhibition and ferroptosis induction for cancer therapy

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6770622B2 (en) * 2001-06-08 2004-08-03 Gary A. Jarvis N-terminally truncated galectin-3 for use in treating cancer
US20040023855A1 (en) 2002-04-08 2004-02-05 John Constance M. Biologic modulations with nanoparticles
US7780912B2 (en) * 2005-08-26 2010-08-24 Lawrence Livermore National Security, Llc Paint for detection of radiological or chemical agents
EP2120050A1 (en) * 2008-05-15 2009-11-18 Steinbeis-Transferzentrum Biopolymeranalytik/Proteomics und Proteinchemie Identification of ligand recognition domains
US8921317B1 (en) 2009-06-12 2014-12-30 Bae Systems Information And Electronic Systems Integration Inc. Nano-recombinant fibrinogen for fibrin sealants
WO2012135528A2 (en) * 2011-03-29 2012-10-04 Texas Tech University System Galectin-3c combination therapy for human cancer
CN104411338A (zh) * 2012-04-02 2015-03-11 现代治疗公司 用于产生与人类疾病相关的生物制剂和蛋白质的修饰多核苷酸
US20150377889A1 (en) * 2013-02-15 2015-12-31 Wayne State University Galectin-3 as a marker for prostate cancer
WO2015051850A1 (en) * 2013-10-11 2015-04-16 Universität Für Bodenkultur Wien Compositions containing galectin-3 modulators for the treatment of bone disorders
US20150157691A1 (en) * 2013-12-05 2015-06-11 Texas Tech University System Galectin-3 to Treat Ovarian Cancer
WO2015117127A1 (en) 2014-02-03 2015-08-06 Texas Tech University System Galectin-3 inhibitor (gal-3m) is associated with additive anti-myeloma and anti-solid tumor effects, decreased osteoclastogenesis and organ protection when used in combination with proteasome inhibitors
CN109310738A (zh) 2016-03-14 2019-02-05 克罗米科股份有限公司 用于治疗癌症的组合物和方法

Also Published As

Publication number Publication date
US10717774B2 (en) 2020-07-21
US20190031732A1 (en) 2019-01-31
WO2017160761A2 (en) 2017-09-21
EP3429613A2 (en) 2019-01-23
CN109310738A (zh) 2019-02-05
WO2017160761A3 (en) 2017-12-07
EP3429613A4 (en) 2020-01-15

Similar Documents

Publication Publication Date Title
PH12018502535A1 (en) Substituted carbonucleoside derivatives useful as anticancer agents
MX2021000710A (es) Composiciones que comprenden cepas bacterianas.
PH12017502002A1 (en) 5`-substituted nucleoside analogs
MY198613A (en) Nitrobenzyl derivatives of anti-cancer agents
MX2019003938A (es) Compuestos espirociclicos.
PH12019502138A1 (en) Compounds and compositions for treating hematological disorders
DK3140319T3 (en) Novel immunotherapy against several tumors of the blood, such as acute myeloid leukemia (aml)
NZ746554A (en) Substituted aminopurine compounds, compositions thereof, and methods of treatment therewith
MX2023010882A (es) Compuestos y composiciones para el tratamiento de trastornos hematológicos.
MX2018009325A (es) Compuestos y metodos para tratar enfermedades mediadas por el acido ribonucleico (arn).
TN2019000211A1 (en) Antitumoral compounds
MX2018011046A (es) Composiciones y metodos para tratar canceres.
MX2018000715A (es) Metodos para tratar cancer usando apilimod.
MX2019005349A (es) Uso de analogos de sangliferina macrociclicos como compuestos anticancerigenos.
ZA201905895B (en) Kits and methods for preparing pathogen-inactivated platelet compositions
WO2017096303A3 (en) Cerdulatinib for treating hematological cancers
EP3847283A4 (en) COMPOUNDS, COMPOSITIONS, AND METHODS FOR TREATMENT OR PREVENTION OF MANAGED CANCER
WO2015181624A3 (en) Nucleoside derivatives for the treatment of cancer
MX379622B (es) Compuestos espirociclicos
MX2021008834A (es) Metodos de tratamiento del cancer de mama con tucatinib.
WO2016130581A3 (en) Combination cancer therapy
JOP20150008B1 (ar) أجسام مضادة ل vista وأجزاء منها
MX2016015568A (es) Derivados de nucleosidos para el tratamiento del cancer.
MX2019001979A (es) Agonista de ppar? para el tratamiento de neoplasias hematicas.
MX2019002947A (es) Combinaciones que incluyen abx196 para el tratamiento de cancer.